IBRANCE (palbociclib) fails trial for early breast cancer treatment
No unexpected safety signals were observed and it did not meet improved invasive disease-free survival in women with HR+, HER2-…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.